Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: "We have always said that we will concentrate on complementary acquisitions in the range of $2 billion to $5 billion." He did not elaborate. Actelion is worth nearly $20 billion at Friday's closing price.
An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday. Interim results from the multi-center trial for 50 patients with acute lymphoblastic leukemia whose cancer returned or did not respond to other treatment, showed that 41 were disease-free three months after treatment with the drug, called CTL019. Novartis estimated that 60 percent of those responders were relapse-free after six months.
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||68.60 x 9000|
|Ask||68.67 x 100|
|Day's Range||67.57 - 68.30|
|52 Week Range||67.28 - 88.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.04|
|Dividend & Yield||2.72 (3.99%)|
|1y Target Est||N/A|